DEXKETOPROFEN
End Stage Renal Disease (ESRD)
Jordan University of Science and TechnologySmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the End Stage Renal Disease (ESRD) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LIDOCAINE The First People's Hospital of Lianyungang | Phase 4 | BB |
ROPIVACAINE The First People's Hospital of Lianyungang | Phase 4 | BB |
METAMIZOLE Jordan University of Science and Technology | N/A | D |
NEPENTHE Jordan University of Science and Technology | N/A | D |
Same molecule, other indications
DEXKETOPROFEN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →